Cibus (CBUS)
NASDAQ:CBUS
Want to see CBUS full AI Analyst Report?
Top Page
Cibus
(NASDAQ:CBUS)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.50
▼(-5.66% Downside)
Action:Reiterated
Date:05/19/26
The score is held back mainly by deep unprofitability and sustained cash burn, alongside weak technical trends. These are partially offset by constructive earnings-call signals—significant cost reductions, extended cash runway after recent financing, and continued commercial/regulatory progress—though the outlook remains highly execution-dependent.
Positive Factors
Technical platform advances
Significant gains in editing efficiency and demonstration of wheat single-cell regeneration materially increase R&D throughput and broaden the trait pipeline. These platform improvements lower per-trait development costs, accelerate partner deliveries, and strengthen long-term competitive differentiation.
Negative Factors
Sustained heavy cash burn
Persistent negative operating and free cash flow at roughly -$50M TTM, large versus a small revenue base, creates a structural funding requirement. Continued high burn constrains strategic choices, increases refinancing risk, and could force dilution or cutbacks if commercial ramps slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Technical platform advances
Significant gains in editing efficiency and demonstration of wheat single-cell regeneration materially increase R&D throughput and broaden the trait pipeline. These platform improvements lower per-trait development costs, accelerate partner deliveries, and strengthen long-term competitive differentiation.
Read all positive factors
Cibus (CBUS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$105.34M
Dividend YieldN/A
Average Volume (3M)154.04K
Price to Earnings (P/E)―
Beta (1Y)2.69
Revenue Growth-9.79%
EPS Growth82.00%
CountryUS
Employees157
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.77
Shares Outstanding76,331,635
10 Day Avg. Volume164,630
30 Day Avg. Volume154,044
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)36.47
Price to Sales (P/S)218.79
P/FCF Ratio-15.56
Enterprise Value/Market Cap2.93
Enterprise Value/Revenue72.00
Enterprise Value/Gross Profit99.90
Enterprise Value/Ebitda-4.95
Forecast
1Y Price Target
$14.67Price Target Upside822.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$7.59M
Cibus Business Overview & Revenue Model
Company Description
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yi...
How the Company Makes Money
null...
Cibus Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call emphasized execution: material commercial progress in LATAM rice (LOI, import permit, delivery of edited materials), clear technical advances (order-of-magnitude improvement in editing efficiency; wheat single-cell regeneration), regulatory tailwinds, and tangible cost reductions that materially improved the P&L and extended runway after raising ~ $37M gross. Offsets include a limited cash runway into Q1 2027 absent stronger near-term revenue, a U.S. rice launch delay from 2028 to 2029 due to herbicide registration timing, continued sizable quarterly net losses and interest on royalty liabilities, and several commercial arrangements still at LOI or early stages. Overall, the positives (capital raise, execution on priority programs, technical and regulatory momentum, and meaningful expense reductions) outweigh the negatives, though the company's trajectory remains execution-dependent.Positive Updates
Significant Capital Raised and Improved Runway
Raised approximately $37 million in gross proceeds across two public offerings ($22.3M in January and ~ $15M in March); cash and cash equivalents of $30.3M as of March 31, 2026. Management expects existing cash plus cost-savings to fund operations into late Q1 2027.
Negative Updates
Cash Runway Still Limited and Dependent on Execution
Cash balance of $30.3M provides runway into late Q1 2027 per management, contingent on hitting near-term commercial revenue and cost targets; further financing may be required if revenue ramp or cost savings do not materialize as planned.
Read all updates
Q1-2026 Updates
Positive
Negative
Significant Capital Raised and Improved Runway
Raised approximately $37 million in gross proceeds across two public offerings ($22.3M in January and ~ $15M in March); cash and cash equivalents of $30.3M as of March 31, 2026. Management expects existing cash plus cost-savings to fund operations into late Q1 2027.
Read all positive updates
Company Guidance
Management reiterated precise near‑term financial and commercial guidance: Cibus closed Q1 with $30.3M cash after raising roughly $37M in gross proceeds ($22.3M in January and ~ $15M in March; >$33M net), which it expects will fund operations into late Q1 2027 while targeting annual net cash usage of approximately $30M or less in 2026 (burn expected to decline Q1→Q2 and be near target in Q3–Q4). Q1 results included R&D expense of $8.7M (vs. $11.8M a year ago), SG&A of $5.1M (vs. $9.9M), operating expenses down nearly $8M YoY, royalty‑liability interest expense of $9.1M (vs. $8.4M), net loss of $21.2M (vs. $49.4M) and net loss per Class A share of $0.33 (vs. $1.34). Commercial milestones and timing guidance included 7 active rice seed‑company relationships, a planned LATAM rice launch in 2027 (the primary thrust of a ~$200M annual addressable royalty opportunity across ~5–7M peak acres), a U.S. rice launch now expected in 2029 (pushed from 2028 pending herbicide registration), anticipated biofragrance scale‑up orders in H2 2026 with the global fragrance market >$65B and potential biofragrance royalties of $20M–$40M annually, and regulatory progress including 17 positive USDA‑APHIS determinations and Ecuador/Peru equivalence determinations enabling LATAM deployment.Cibus Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.29M | 3.64M | 4.26M | 1.82M | 157.00K | 25.99M |
| Gross Profit | 3.09M | -2.28M | 4.26M | 1.42M | -1.38M | -2.57M |
| EBITDA | -62.31M | -90.77M | -241.63M | -314.58M | -15.21M | -25.43M |
| Net Income | -101.42M | -127.08M | -251.39M | -267.63M | -16.89M | -29.20M |
Balance Sheet | ||||||
| Total Assets | 324.20M | 305.05M | 350.07M | 544.41M | 22.42M | 37.19M |
| Cash, Cash Equivalents and Short-Term Investments | 30.32M | 9.92M | 14.43M | 32.70M | 3.43M | 13.82M |
| Total Debt | 276.15M | 267.96M | 36.29M | 24.62M | 13.91M | 17.88M |
| Total Liabilities | 288.72M | 283.22M | 252.24M | 206.12M | 15.19M | 23.06M |
| Stockholders Equity | 35.48M | 21.83M | 92.16M | 293.47M | 7.23M | 14.13M |
Cash Flow | ||||||
| Free Cash Flow | -50.65M | -51.17M | -58.85M | -50.53M | -20.88M | -19.31M |
| Operating Cash Flow | -50.25M | -50.59M | -58.04M | -46.21M | -19.36M | -18.81M |
| Investing Cash Flow | -359.00K | -578.00K | -808.00K | 55.06M | -1.52M | 11.20M |
| Financing Cash Flow | 57.34M | 46.65M | 40.60M | 20.32M | 9.99M | 3.74M |
Cibus Technical Analysis
Negative
1.59
Price Trends
1.80
Negative
2.15
Negative
1.79
Negative
Market Momentum
-0.11
Negative
42.75
Neutral
62.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Negative. The current price of 1.59 is above the 20-day moving average (MA) of 1.42, below the 50-day MA of 1.80, and below the 200-day MA of 1.79, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 42.75 is Neutral, neither overbought nor oversold. The STOCH value of 62.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CBUS.
Cibus Risk Analysis
Cibus disclosed 44 risk factors in its most recent earnings report. Cibus reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cibus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $381.05M | -6.44 | -94.90% | ― | -71.26% | -300.04% | |
48 Neutral | $105.34M | -15.21 | -225.59% | ― | -9.79% | 82.00% | |
44 Neutral | $28.33M | -1.15 | -136.08% | ― | -77.56% | -50.38% | |
43 Neutral | $29.64M | -3.96 | -88.89% | ― | -100.00% | -170.04% | |
42 Neutral | $83.73M | -7.23 | 102.92% | ― | ― | ― |
* Healthcare Sector Average
CBUS
Cibus
1.38
-1.47
-51.58%
CRVO
CervoMed
3.06
-4.90
-61.56%
XFOR
X4 Pharmaceuticals
4.04
0.65
19.17%
ABVC
ABVC BioPharma
1.14
-0.24
-17.39%
OKYO
OKYO Pharma Limited Sponsored ADR
1.63
-0.12
-6.86%
Cibus Corporate Events
Business Operations and StrategyExecutive/Board Changes
Cibus Strengthens Board with Appointment of Thomas Urban
Positive
Apr 10, 2026
On April 7, 2026, Cibus, Inc. appointed Thomas Urban, founder of Agribusiness Advisors and former chief executive of CellFor, Inc., to its Board of Directors, adding deep agribusiness, investment and global leadership experience to its governance....
Private Placements and Financing
Cibus Launches Underwritten Public Offering of Common Stock
Neutral
Mar 27, 2026
On March 25, 2026, Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for an underwritten public offering of 6,976,744 shares of its Class A common stock at $2.15 per share, with a 30-day option for the underwriter to purchase up to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.